Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder

被引:0
|
作者
Zilcha-Mano, Sigal [1 ]
Brown, Patrick J. [2 ]
Roose, Steven P. [2 ]
Cappetta, Kiley [2 ]
Rutherford, Bret R. [2 ]
机构
[1] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel
[2] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA
关键词
expectancy; major depressive disorder; placebo effects; PLACEBO-RESPONSE; BETWEEN-PERSON; WITHIN-PERSON; METAANALYSIS; DESIGN; ALLIANCE; QUESTION; MODELS;
D O I
10.1017/S0033291718003343
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Patient expectancy is an important source of placebo effects in antidepressant clinical trials, but all prior studies measured expectancy prior to the initiation of medication treatment. Little is known about how expectancy changes during the course of treatment and how such changes influence clinical outcome. Consequently, we undertook the first analysis to date of in-treatment expectancy during antidepressant treatment to identify its clinical and demographic correlates, typical trajectories, and associations with treatment outcome. Methods Data were combined from two randomized controlled trials of antidepressant medication for major depressive disorder in which baseline and in-treatment expectancy assessments were available. Machine learning methods were used to identify pre-treatment clinical and demographic predictors of expectancy. Multilevel models were implemented to test the effects of expectancy on subsequent treatment outcome, disentangling within- and between-patient effects. Results Random forest analyses demonstrated that whereas more severe depressive symptoms predicted lower pre-treatment expectancy, in-treatment expectancy was unrelated to symptom severity. At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003). The greater the gap between expected treatment outcomes and actual depressive severity, the greater the subsequent symptom reductions were (B = 0.49, t = 2.33, p = 0.02). Conclusions Greater in-treatment patient expectancy is associated with greater subsequent depressive symptom reduction. These findings suggest that clinicians may benefit from monitoring and optimizing patient expectancy during antidepressant treatment. Expectancy may represent another treatment parameter, similar to medication compliance and side effects, to be regularly monitored during antidepressant clinical management.
引用
收藏
页码:2414 / 2420
页数:7
相关论文
共 50 条
  • [21] DEPRESSIVE PERSONALITY AND TREATMENT OUTCOME IN MAJOR DEPRESSIVE DISORDER
    Ryder, Andrew G.
    Quilty, Lena C.
    Vachon, David D.
    Bagby, R. Michael
    JOURNAL OF PERSONALITY DISORDERS, 2010, 24 (03) : 392 - 404
  • [22] Cytokine profile of patient with major depressive disorder
    Babusikova, E.
    Ondrejka, I.
    Hrtanek, I.
    Dobrota, D.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 81 - 81
  • [23] Major depressive disorder - understanding the patient journey
    Baune, B. T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S48 - S49
  • [24] A Major Depressive Disorder in a Patient with Pseudobulbar Affect
    Espiridion, Eduardo D.
    Risos, Kyle N.
    CUREUS, 2018, 10 (12):
  • [25] Aripiprazole monotherapy in a patient with major depressive disorder
    Yokoyama, Yuichi
    Kitamura, Hideaki
    Someya, Toshiyuki
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2010, 34 (06): : 1124 - 1125
  • [26] Patient-reported outcomes before and after treatment of major depressive disorder
    IsHak, Waguih William
    Mirocha, James
    Pi, Sarah
    Tobia, Gabriel
    Becker, Bret
    Peselow, Eric D.
    Cohen, Robert M.
    DIALOGUES IN CLINICAL NEUROSCIENCE, 2014, 16 (02) : 171 - 183
  • [27] OPTIMIZING TREATMENT EFFICACY: RTMS VS. ITBS IN MAJOR DEPRESSIVE DISORDER MANAGEMENT IN TAIWAN
    Tien, Yun
    Huang, Shang-Chien
    Huang, Hsiang-Ping
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i195 - i196
  • [28] Pharmacologic treatment of postpartum women with new-onset major depressive disorder: A randomized controlled trial with paroxetine
    Yonkers, Kimberly A.
    Lin, Haiqun
    Howell, Heather B.
    Heath, A. Christopher
    Cohen, Lee S.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (04) : 659 - 665
  • [29] Psychopharmacologic treatment of pediatric major depressive disorder
    Khrista Boylan
    Soledad Romero
    Boris Birmaher
    Psychopharmacology, 2007, 191 : 27 - 38
  • [30] Anticonvulsants in the Treatment of Major Depressive Disorder: An Overview
    Vigo, Daniel V.
    Baldessarini, Ross J.
    HARVARD REVIEW OF PSYCHIATRY, 2009, 17 (04) : 231 - 241